Wednesday, April 3, 2019
Trovagene Inc. (TROV)
Updated early prostate cancer data demonstrates sustained PSA levels.
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- AACR
Presentation. The company had the second presentation from a Phase 2 study
of onvansertib in combination with Zytiga/prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC), at the American Association for
Cancer Research (AACR) annual meeting today, following the update from the
acute myeloid leukemia (AML) trial (refer to the note published on April 2nd,
2019). - Data Update in
Prostate Cancer. Onvansertib in combination with Zytiga/prednisone treatment
achieved a reduction of prostate specific antigen (PSA) levels in 2 out of
6 mCRPC patients. The previous data reported at
the Genitourinary Cancers Symposium (ASCO-GU, on February) showed
reduced PSA levels, however levels were relapsed. The company plans to
comm…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.